辛伐他汀对急性冠脉综合征患者血清基质金属蛋白酶-9及其组织抑制因子-1的影响

目的观察辛伐他汀对急性冠脉综合征（ACS）患者血清基质金属蛋白酶-9（MMP-9）及其组织抑制因子-1（TIMP-1）的影响。方法选择ACS患者4JD例（ACS组）、稳定性心绞痛（SAP）患者34例（SAP组）、健康体检者25例（对照组），采用酶联免疫吸附法测定其血清可溶性TIMP-1及MMP-9水平，辛伐他汀治疗后复查TIMP-1及MMP-9水平变化。结果ACS组血清MMP-9水平（930±127）μg/L高于SAP组的（619±114）μg／L及对照组的（417±105）μg／L（均P〈0．05），而TIMP-1水平（73±14）μg／L显著低于SAP组的（121±17）μg/L及对照组的（151±24）μg／L（均P〈0．05）；辛伐他汀治疗4周后ACS组血清MMPO水平为（641±123）μg／L、TIMP-1水平为（114±18）μg/L，与治疗前比较差异均有统计学意义（P〈0．01，P〈0．05），SAP组治疗后MMP-9水平为（546±122）μg/L，与治疗前比较差异具有统计学意义（P〈0．05），而TIMP-1水平无明显改变（P〉0．05）。结论MMP-9及TIMP-1可能与ACS发病密切相关，监测其血清水平对ACS的治疗有重要的指导意义。

Effect of simvastatin on serum level of matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in patients with acute coronary syndromes

Objective To observe the effect of simvastatin on serum levels of matrix metalloproteinase-9(MMP-9) and tissue inhibitors of matrix metalloproteinase-1 (TIMP-1) in patients with acute coronary syndromes (ACS).Methods 74 patients with coronary heart disease were studied.Among them,there were 34 patients with stable angina pectoris(SAP) and 40 patients with ACS.At the same time 25 cases of age matched healthy individuals were selected as a control.The serum level of MMP-gand TIMP-1 were compared among all groups.Results There was a significant difference in serum level of MMP-9and TIMP-1 among SAP group,ACS group and control group.The serum level of MMP-9 and TIMP-1 were different after treatment.Conclusion Plaque disruption may be related to the increased serum level of MMP-9 and the decreased serum level of TIMP-1 .Simvastatin can decrease serum level of MMP-9 and increase serum level of TIMP-1 in patients with ACS,and it may have a beneficial effect on clinical treating of patients with ACS.